drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous macrophages)
drug_description
Gene-modified autologous macrophages expressing an anti-HER2 chimeric antigen receptor (CAR). Derived from patient PBMCs, differentiated to macrophages, transduced ex vivo via an adenoviral vector, and administered intraperitoneally to induce HER2-dependent tumor cell phagocytosis and cytotoxicity and remodel the tumor microenvironment.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor
drug_category
CAR M
drug_class
Cellular Therapy
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor bind HER2 on tumor cells, activating macrophage phagocytosis and cytotoxicity and remodeling the tumor microenvironment to enhance anti-tumor immunity.
drug_name
Autologous HER2-targeted CAR-M cells
nct_id_drug_ref
NCT06224738